We are extremely pleased by these results. We believe that they are the first validation of the therapeutic vaccination approach in infectious diseases. These data constitute a significant breakthrough and validate our vaccine technology platform. Our objective is an effective vaccine for pre-cancerous lesions to speed up the fight against cervical cancer which remains a serious health concern globally.